The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Therapeutic monoclonal antibodies in ophthalmology
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 2×
“VEGF is a family of proteins that includes placenta growth factor (PlGF), VEGF-A, VEGF-B, VEGF-C, VEGF-D and the viral VEGF homologue VEGF-E (Ferrara et al., 2001, 2003).”
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886 · cited 3×
“Minor ocular events included conjunctival bleeding, ocular pain, and floaters (Rosenfeld et al., 2006a).”
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456 · cited 2×
“%) deaths (Wu et al., 2008).”
Self-citationHuman antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Kaiser, P. K., Brown, D. M., Zhang, K., Hudson, H. L., Holz, F. G., Shapiro, H., Schneider, S., & Acharya, N. R. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.08.012 · Cited by 361 · cited 1×
“…ANCHOR study showed that 94% or more of patients treated with ranibizumab maintained VA compared to 64% of patients treated with PDT, while patients with ranibizumab had an average increase of 8.5 letters (0.3 mg ranibizumab) and 11.3 letters (0.5 mg ranibizumab) in mean VA (Kaiser et al., 2007).”
InfluentialFully human therapeutic monoclonal antibodies.
Weiner, L. M. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000192105.24583.83 · Cited by 164
Cited by
Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment
Du, L., Kijlstra, A., & Yang, P. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.02.002 · Cited by 254
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
“Increased knowledge of the molecular mechanisms of blinding diseases (Rodrigues et al., 2009; de Oliveira Dias et al., 2011) has driven the development of therapeutic proteins including antibody-based medicines (Penedones et al., 2014).”
Melo, G. B., Cruz, N. F. S. D., Emerson, G. G., Rezende, F. A., Meyer, C. H., Uchiyama, S., Carpenter, J., Shiroma, H. F., Farah, M. E., Maia, M., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100862 · Cited by 114
Self-citationOh, E. J., Choi, J.-S., Kim, H., Joo, C.-K., & Hahn, S. K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.003 · Cited by 77
A heparin mimetic isolated from a marine shrimp suppresses neovascularization
DREYFUSS, J. L., REGATIERI, C. V., LIMA, M. A., PAREDES‐GAMERO, E. J., BRITO, A. S., CHAVANTE, S. F., BELFORT JR, R., FARAH, M. E., & NADER, H. B. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03916.x · Cited by 38
Self-citation
Metadata
- Authors
- Rodrigues, E. B., Farah, M. E., Maia, M., Penha, F. M., Regatieri, C., Melo, G. B., Pinheiro, M. M., & Zanetti, C. R.
- Venue
- Progress in Retinal and Eye Research
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 28
- Issue
- 2
- Pages
- 117-144
- ISSN
- 1350-9462 (ISSN-L)
- OpenAlex
- W2029207164
- Cited by
- 173
- References
- 7
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.